Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 19/20 | 0.93 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.93 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6723538 | 0.97 | ADORA3 (1.00) | ADORA3ADORA2AADORA1 | |
| SCHEMBL6716491 | 0.92 | ADORA3 (0.93) | ADORA3ADORA2AADORA1 | |
| SCHEMBL6715370 | 0.91 | ADORA3 (0.93) | ADORA3ADORA2AADORA1KDM4EHSP90AB1 | |
| SCHEMBL6718573 | 0.91 | ADORA3 (0.90) | ADORA3ADORA2AADORA1 | |
| SCHEMBL6719480 | 0.89 | ADORA3 (0.93) | ADORA3ADORA2AADORA1 | |
| SCHEMBL6716700 | 0.89 | ADORA3 (0.93) | ADORA3ADORA2AADORA1 | |
| SCHEMBL6714205 | 0.89 | ADORA3 (0.93) | ADORA3ADORA2AADORA1 | |
| SCHEMBL6723233 | 0.88 | ADORA3 (1.00) | ADORA3ADORA2AADORA1 | |
| SCHEMBL6715414 | 0.88 | ADORA3 (1.00) | ADORA3ADORA2AADORA1 | |
| SCHEMBL6716964 | 0.87 | ADORA3 (1.00) | ADORA3ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142952-A1 | Triazoloquinazoline and pyrazolotriazolopyrimidine derivatives, medicinal compositions, adenosine a3 receptor affinity agents, ocular tension lowering agents, preparations for preventing and treating glaucoma and method of lowering ocular tension | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2004-07-22 | — | — | US | disclosed |
| EP-1364953-A1 | TRIAZOLOQUINAZOLINE AND PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES, MEDICINAL COMPOSITIONS, ADENOSINE A3 RECEPTOR AFFINITY AGENTS, OCULAR TENSION LOWERING AGENTS, PREPARATIONS FOR PREVENTING AND TREATING GLAUCOMA AND METHOD OF LOWERING OCULAR TENSION | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2003-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142952-A1 | Triazoloquinazoline and pyrazolotriazolopyrimidine derivatives, medicinal compositions, adenosine a3 receptor affinity agents, ocular tension lowering agents, preparations for preventing and treating glaucoma and method of lowering ocular tension | ADORA3, ADORA1, ADORA2A | ADORA3 1/4885ADORA2A 3/4885ADORA1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.